Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Henson

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
F1000Research|May 11, 2017
A double blinded, placebo-controlled pilot study to examine reduction of CD34 <sup>+</sup>/CD117 <sup>+</sup>/CD133 <sup>+</sup> lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphomaDaisuke Ito, Michael Childress, Nicola Mason, et al.
Plos One|March 19, 2014
Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trialsMelissa Paoloni, Craig Webb, Christina Mazcko, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
F1000Research|May 11, 2017
A double blinded, placebo-controlled pilot study to examine reduction of CD34 <sup>+</sup>/CD117 <sup>+</sup>/CD133 <sup>+</sup> lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphomaDaisuke Ito, Michael Childress, Nicola Mason, et al.
Plos One|March 19, 2014
Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trialsMelissa Paoloni, Craig Webb, Christina Mazcko, et al.
Pageof 2